Market Research Reports, Inc. has announced the addition of “US Market for Heart Defect Closure Devices - 2016 (Forecasted to 2022)” research report to their website www.MarketResearchReports.com

Lewes, DE -- (SBWire) -- 10/16/2015 --As of August 2015, the FDA had not approved a device for PFO closure. Therefore, device-based patent foramen ovale (PFO) closure procedures are most commonly performed using atrial septal defect (ASD) closure devices being used off-label. Despite the lack of FDA approval, PFO closure remains popular due to the reduced risk of stroke and the reduced frequency of migraines. Over 2.5 million men and women suffer from atrial fibrillation (AF) in the United States. With many AF patients hesitant to take anti-coagulant medication, a huge patient population exists for left atrial appendage (LAA) closure devices in the United States. Endocardial LAA closure devices present a minimally invasive option for LAA management.

As of August 2015, the U.S. market for endocardial LAA closure devices was composed entirely of Boston Scientific's WATCHMAN™ device, which received FDA approval in March 2015. The large AF patient population, reports of negative patient outcomes with other methods of LAA closure and patient preference for minimally invasive treatment techniques will combine to drive unit sales of the endocardial LAA segment to grow at a CAGR in excess of 60% over the forecast period. The rapidly increasing unit sales of the endocardial LAA segment will interact with the high ASP of the WATCHMAN™ to urge massive growth in the value of the total U.S. market for LAA devices.

This Report Includes Segments On:
- Patent Foramen Ovale Devices
- Atrial and Ventricular Septal Defect Devices
- Left Atrial Appendage Closure Device Market

This 78 Page Report Includes:
- In-depth, Professionally Researched Data That Has Been Formatted and Analyzed to Gain Actionable Insights as Quickly as Possible
- Executive Summary
- Trend Analysis by Segment
- Market Value Forecasts until 2022 and History Back to 2012
- Market Drivers and Limiters
- Detailed Competitive Analysis for Each Market and Segment

While PFO closure devices have the largest share of the U.S. market for PFO, ASD & ventricular septal defect (VSD) closure devices, VSD closure devices have the smallest share. Historically, the size of the VSD closure device segment had been limited by the number of patients requiring treatment for VSDs, which has remained much smaller than the number of patients requiring treatment for ASD or PFO. Over 2.5 million men and women suffer from atrial fibrillation (AF) in the United States. With many AF patients hesitant to take anti-coagulant medication, a huge patient population exists for left atrial appendage (LAA) closure devices in the United States.

Spanning over 78 pages "US Market for Heart Defect Closure Devices - 2016 (Forecasted to 2022)" report covers Executive Summary, Research Methodology, Patent Foramen Ovale Device Market, Atrial & Ventricular Septal Defect Device Market, Left Atrial Appendage Closure Device Market. The report covered companies are - AtriCure, Boston Scientific, St. Jude Medical, SentreHeart, W.L. Gore

For further information on this report, please visit- http://www.marketresearchreports.com/idata-research/us-market-heart-defect-closure-devices-2016-forecasted-2022

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions